PRCT PROCEPT BioRobotics Corp

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001588978
AI RATING
HOLD
63% Confidence

Investment Thesis

PROCEPT demonstrates strong revenue growth of 37.2% YoY with excellent 64.9% gross margins, indicating solid product-market fit and pricing power. However, significant operating losses (-39.2% margin) and negative free cash flow (-$41M) reveal the company is not yet profitable despite healthy gross margins, requiring operational leverage improvement. The fortress balance sheet with $245.6M cash and low debt (0.15x) provides 6+ year runway, but a credible path to profitability must emerge.

Strengths

  • + Revenue growth of 37.2% YoY demonstrates strong market demand for surgical robotics
  • + Gross margin of 64.9% indicates strong pricing power and efficient core operations
  • + Fortress balance sheet: $245.6M cash, 0.15x debt-to-equity, 6.73x current ratio provides substantial runway

Risks

  • ! Operating margin of -39.2% and net margin of -38.1% show inability to achieve profitability despite strong gross margins
  • ! Negative operating cash flow of -$38.1M and free cash flow of -$41.0M indicates ongoing cash burn with unclear path to positive FCF
  • ! Operating expenses are not declining relative to revenue growth; company must demonstrate operating leverage to justify continued losses

Key Metrics to Watch

Financial Metrics

Revenue
83.1M
Net Income
-31.6M
EPS (Diluted)
$-0.56
Free Cash Flow
-41.0M
Total Assets
487.1M
Cash
245.6M

Profitability Ratios

Gross Margin 64.9%
Operating Margin -39.2%
Net Margin -38.1%
ROE -9.1%
ROA -6.5%
FCF Margin -49.4%

Balance Sheet & Liquidity

Current Ratio
6.73x
Quick Ratio
5.51x
Debt/Equity
0.15x
Debt/Assets
28.6%
Interest Coverage
-31.20x
Long-term Debt
51.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T16:07:44.926064 | Data as of: 2026-03-31 | Powered by Claude AI